Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Triptorelin Pamoate

FDA-approved product (injectable, intramuscular), marketed as Trelstar, Triptodur Kit.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Triptorelin Pamoate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Central precocious puberty
  • Metastatic prostate cancer
  • Neoplasm
  • Precocious puberty
  • Prostate adenocarcinoma
  • Prostate carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Gonadotropin releasing hormone analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli55.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Triptorelin Pamoate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Triptorelin Pamoate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Intranasal Nafarelin For Triggering Oocyte Maturation

    NCT06763926 · start 2026-10-15

    Registered record
    Registry ID
    NCT06763926
    Conditions
    Fertility Preservation
    Interventions
    Subcutaneous Triptorelin; Intranasal nafarelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-10-15
    Completion
    2028-01-15
    Enrolment
    154

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFertility Preservation
    InterventionSubcutaneous Triptorelin; Intranasal nafarelin
    PhasePhase 4
    Registry statusNot yet recruiting

  • Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer

    NCT07389174 · start 2026-02

    Registered record
    Registry ID
    NCT07389174
    Conditions
    mHSPC; mHNPC; Prostate Cancer Adenocarcinoma
    Interventions
    Standard Endocrine Therapy; LC-K76
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Not yet recruiting
    Start
    2026-02
    Completion
    2027-06
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionmHSPC; mHNPC; Prostate Cancer Adenocarcinoma
    InterventionStandard Endocrine Therapy; LC-K76
    PhaseEarly phase 1
    Registry statusNot yet recruiting

  • Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification

    NCT07319429 · start 2026-01-25

    Registered record
    Registry ID
    NCT07319429
    Conditions
    Endometrial Cancer; Fertility
    Interventions
    PD1 antibody; Medroxyprogesterone Acetate 500 MG; Megestrol Acetate 160 MG; GnRH agonist and Letrozole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2026-01-25
    Completion
    2029-12-31
    Enrolment
    260

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometrial Cancer; Fertility
    InterventionPD1 antibody; Medroxyprogesterone Acetate 500 MG; Megestrol Acetate 160 MG; GnRH agonist and Letrozole
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • The COSMYC Trial (COmbined Suppression of MYC)

    NCT06922318 · start 2025-08-19

    Registered record
    Registry ID
    NCT06922318
    Conditions
    Metastatic Castration-resistant Prostate Cancer
    Interventions
    ZEN-3694; Testosterone cypionate; Enzalutamide; Luteinizing hormone-releasing hormone (LHRH) analogue
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-08-19
    Completion
    2031-08-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-resistant Prostate Cancer
    InterventionZEN-3694; Testosterone cypionate; Enzalutamide; Luteinizing hormone-releasing hormone (LHRH) analogue
    PhasePhase 2
    Registry statusRecruiting

  • Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients

    NCT06832774 · start 2025-08-01

    Registered record
    Registry ID
    NCT06832774
    Conditions
    Prostate Cancer Metastatic Disease
    Interventions
    Local treatment; Gonadotropin releasing hormone analog (GnRHa) + Novel hormone therapy (abiraterone, apalutamide or rezvilutamide).
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-08-01
    Completion
    2028-12-31
    Enrolment
    192

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer Metastatic Disease
    InterventionLocal treatment; Gonadotropin releasing hormone analog (GnRHa) + Novel hormone therapy (abiraterone, apalutamide or rezvilutamide).
    PhasePhase 2
    Registry statusRecruiting

  • Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate Cancer

    NCT06795178 · start 2025-07-01

    Registered record
    Registry ID
    NCT06795178
    Conditions
    Prostate Cancer
    Interventions
    FP-014
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2025-07-01
    Completion
    2028-02-02
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionFP-014
    PhasePhase 3
    Registry statusWithdrawn

  • Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF/ICSI Cycles

    NCT06150703 · start 2024-06-27

    Registered record
    Registry ID
    NCT06150703
    Conditions
    In Vitro Fertilization; ICSI Intracytoplasmic Spermatozoid Injection
    Interventions
    Ovulation induction with hCG + Luteal phase support with vaginal progesterone; Ovulation triggering by Triptorelin + Luteal phase support by Nafarelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-06-27
    Completion
    2027-09-27
    Enrolment
    652

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIn Vitro Fertilization; ICSI Intracytoplasmic Spermatozoid Injection
    InterventionOvulation induction with hCG + Luteal phase support with vaginal progesterone; Ovulation triggering by Triptorelin + Luteal phase support by Nafarelin
    PhasePhase 3
    Registry statusRecruiting

  • Surgery and ART For Endometrioma

    NCT03717870 · start 2023-10

    Registered record
    Registry ID
    NCT03717870
    Conditions
    Ovarian Endometrioma; Infertility, Female
    Interventions
    Laparoscopic enucleation of ovarian endometrioma.; Prolonged pituitary downregulation; Assisted Reproductive Technology (ART)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2023-10
    Completion
    2027-10
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Endometrioma; Infertility, Female
    InterventionLaparoscopic enucleation of ovarian endometrioma.; Prolonged pituitary downregulation; Assisted Reproductive Technology (ART)
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624

    NCT05781217 · start 2023-03-14

    Registered record
    Registry ID
    NCT05781217
    Conditions
    Prostate Cancer; Salvage Radiotherapy; Biochemical Recurrence; Androgen Deprivation Therapy; Metastases-free Survival
    Interventions
    triptorelin, goserelin, leuprorelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-03-14
    Completion
    2032-12
    Enrolment
    534

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Salvage Radiotherapy; Biochemical Recurrence; Androgen Deprivation Therapy +1 more
    Interventiontriptorelin, goserelin, leuprorelin
    PhasePhase 3
    Registry statusRecruiting

  • Evaluate the Effectiveness of Progestin-Primed Versus GnRH Antagonist Protocols in Vietnamese Women Undergoing In-vitro Fertilization

    NCT06191809 · start 2023-02-14

    Registered record
    Registry ID
    NCT06191809
    Conditions
    IVF
    Interventions
    Controlled Ovarian Stimulation Protocol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-02-14
    Completion
    2024-12-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIVF
    InterventionControlled Ovarian Stimulation Protocol
    PhaseNot applicable
    Registry statusUnknown

  • Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

    NCT05701007 · start 2023-02-13

    Registered record
    Registry ID
    NCT05701007
    Conditions
    Metastatic Castration Sensitive Prostate Cancer (mCSPC); Metastatic Castration Resistant Prostate Cancer (mCRPC)
    Interventions
    abiraterone; enzalutamide; docetaxel; apalutamide; cabazitaxel; Radium-223; Lutetium-177; degarelix; goserelin; leuprorelin; triptorelin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-02-13
    Completion
    2024-04-10
    Enrolment
    1,083

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration Sensitive Prostate Cancer (mCSPC); Metastatic Castration Resistant Prostate Cancer (mCRPC)
    Interventionabiraterone; enzalutamide; docetaxel; apalutamide +7 more
    PhaseNot recorded
    Registry statusCompleted

  • Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

    NCT05498272 · start 2023-02-01

    Registered record
    Registry ID
    NCT05498272
    Conditions
    Prostate Cancer; BRCA1 Mutation; BRCA2 Mutation; Prostatic Adenocarcinoma; High-Risk Cancer
    Interventions
    Olaparib; LHRH agonist
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-02-01
    Completion
    2026-12
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; BRCA1 Mutation; BRCA2 Mutation; Prostatic Adenocarcinoma +1 more
    InterventionOlaparib; LHRH agonist
    PhasePhase 2
    Registry statusActive not recruiting

  • DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte Maturation

    NCT04616729 · start 2022-11-01

    Registered record
    Registry ID
    NCT04616729
    Conditions
    Breast Cancer Female
    Interventions
    Triptorelin 3.75 MG Injection; Transvaginal oocyte retrieval; Triptorelin Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2022-11-01
    Completion
    2025-12-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer Female
    InterventionTriptorelin 3.75 MG Injection; Transvaginal oocyte retrieval; Triptorelin Injection
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate

    NCT05458856 · start 2022-08-30

    Registered record
    Registry ID
    NCT05458856
    Conditions
    Prostate Cancer
    Interventions
    Triptorelin embonate 22.5 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-08-30
    Completion
    2024-07-08
    Enrolment
    147

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionTriptorelin embonate 22.5 mg
    PhasePhase 3
    Registry statusCompleted

  • Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer Treatment

    NCT05377684 · start 2022-06-09

    Registered record
    Registry ID
    NCT05377684
    Conditions
    Early-stage Breast Cancer
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-06-09
    Completion
    2026-06-04
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEarly-stage Breast Cancer
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted